Plasma-based tumor mutational profiling is arising as a reliable approach to detect primary and therapy-induced resistance mutations required for accurate treatment decision making. Here, we compared the FDA-approved Cobas® EGFR Mutation Test v2 with the UltraSEEK™ Lung Panel on the MassARRAY® System on detection of EGFR mutations, accompanied with preanalytical sample assessment using the novel Liquid IQ® Panel. 137 cancer patient-derived cell-free plasma samples were analyzed with the Cobas® and UltraSEEK™ tests. Liquid IQ® analysis was initially validated (n = 84) and used to determine ccfDNA input for all samples. Subsequently, Liquid IQ® results were applied to harmonize ccfDNA input for the Cobas® and UltraSEEK™ tests for 63 NSCLC patients. The overall concordance between the Cobas® and UltraSEEK™ tests was 86%. The Cobas® test detected more EGFR exon19 deletions and L858R mutations, while the UltraSEEK™ test detected more T790M mutations. A 100% concordance in both the clinical (n = 137) and harmonized (n = 63) cohorts was observed when >10 ng of ccfDNA was used as determined by the Liquid IQ® Panel. The Cobas® and UltraSEEK™ tests showed similar sensitivity in EGFR mutation detection, particularly when ccfDNA input was sufficient. It is recommended to preanalytically determine the ccfDNA concentration accurately to ensure sufficient input for reliable interpretation and treatment decision making.
11 July 2019 in Breast Cancer Research and Treatment
Analysis of circulating tumor DNA (ctDNA) is a potential minimally invasive molecular tool to guide treatment decision-making and disease monitoring. A suitable diagnostic-grade platform is required for the detection of tumor-specific mutations with high sensitivity in the circulating cell-free DNA (ccfDNA) of cancer patients. In this multicenter study, the ccfDNA of 72 patients treated for advanced-stage non-small cell lung cancer (NSCLC) was evaluated using the UltraSEEK® Lung Panel on the MassARRAY® System, covering 73 hotspot mutations in EGFR, KRAS, BRAF, ERBB2, and PIK3CA against mutation-specific droplet digital PCR (ddPCR) and routine tumor tissue NGS. Variant detection accuracy at primary diagnosis and during disease progression, and ctDNA dynamics as a marker of treatment efficacy, were analyzed. A multicenter evaluation using reference material demonstrated an overall detection rate of over 90% for variant allele frequencies (VAFs) > 0.5%, irrespective of ccfDNA input. A comparison of UltraSEEK® and ddPCR analyses revealed a 90% concordance. An 80% concordance between therapeutically targetable mutations detected in tumor tissue NGS and ccfDNA UltraSEEK® analysis at baseline was observed. Nine of 84 (11%) tumor tissue mutations were not covered by UltraSEEK®. A decrease in ctDNA levels at 4–6 weeks after treatment initiation detected with UltraSEEK® correlated with prolonged median PFS (46 vs. 6 weeks; p < 0.05) and OS (145 vs. 30 weeks; p < 0.01). Using plasma-derived ccfDNA, the UltraSEEK® Lung Panel with a mid-density set of the most common predictive markers for NSCLC is an alternative tool to detect mutations both at diagnosis and during disease progression and to monitor treatment response.
Metastasis is a multistep process involving tumor and stromal cells. The microanatomical site consisting of a perivascular macrophage interacting with a Mena over-expressing tumor cell has been named the “tumor microenvironment of metastasis” (TMEM). TMEM density predicts distant metastatic recurrence in breast cancer patients making the study of TMEM function essential. In spontaneous orthotopic mouse mammary tumors (MMTV-PyMT), as the tumor progresses to malignancy tumor cells have increased Mena expression and assemble TMEM. TMEM assembly is correlated with elevated levels of circulating tumor cells and lung metastases, indicating a functional role for TMEM in tumor cell dissemination. High-resolution multiphoton-based microscopy at single cell resolution has revealed transient blood vessel permeability events at TMEM, marked by the extravasation of otherwise impermeable serum markers such as Qdots and fluorescent 155 kDa dextran. In proximity to sites of permeability there is increased tumor cell and macrophage motility towards the blood vessel, and local intravasation of tumor cells. Blocking macrophage function results in decreased blood vessel permeability and decreased numbers of circulating tumor cells. TMEM-associated macrophages produce VEGF-A, and blocking VEGF-A reduces blood vessel permeability and circulating tumor cells. The observation that TMEM mediates tumor cell intravasation through localized blood vessel permeability in live animals demonstrates that TMEM is a key metastatic microenvironment in the primary tumor, explains the prognostic value of TMEM density in predicting distant metastatic recurrence in breast cancer patients and suggests a potentially valuable re-tasking of existing anti-angiogenesis drugs.